Latest North America News

Stonehorse Energy Limited reported steady operational performance in Q4 2025, driven by strong production from a new Drumheller well in Alberta and maintaining a solid cash position of A$4.86 million.

HITIQ has made significant strides in expanding its concussion management technology, PROTEQT©, into North America and Australian retail, backed by strong research partnerships and a successful capital raise.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Terra Critical Minerals has completed a key acquisition in Nevada and boosted its Canadian uranium investment, positioning itself to capitalise on soaring tungsten and uranium prices.

Lithium Universe Limited (ASX, LU7) reports major advances in silver recycling technology alongside plans for a second lithium refinery in Texas, supported by a $2.5 million capital raise.

Recharge Metals Limited progresses uranium exploration in the USA and Canada while appointing a new director and maintaining disciplined capital management.

IODM Limited has reported a standout Q2 FY26 with record cash receipts driven by strong UK education sector growth and strategic board renewal.

Mont Royal Resources has kicked off a comprehensive work program at its Ashram Rare Earth and Fluorspar Project following a transformative merger and a successful $10 million capital raise. An updated Preliminary Economic Assessment is expected by the end of Q1 2026.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

Janus Electric reports operational progress with validated technology and increased revenue, while focusing on commercial execution and cost discipline under new CEO Ben Hutt. Funding remains a critical factor for sustaining growth.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Beonic Limited has secured a $7.3 million contract phase for its Moroccan Airports project, completed a $4.27 million capital raise, and fully repaid a $4.65 million USD loan, underpinning its continued EBITDA profitability and positive cash flow.